Analytical Data
-
Gene name
ZNF384
- Application
-
Alternative Names
CAG repeat protein 1 CAS-interacting zinc finger protein Nuclear matrix transcription factor 4 Short name: Nuclear matrix protein 4 Trinucleotide repeat-containing gene 1 protein
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TF68
-
Expression Region
1-245aa
-
Molecular Weight
53.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ZNF384 is a zinc finger protein that has garnered significant interest due to its role in various biological processes and its implications in cancer biology. Studies have shown that ZNF384 is involved in gene regulation and is implicated in the development and progression of hematological malignancies, such as acute lymphoblastic leukemia (ALL). Notably, ZNF384 gene rearrangements have been associated with poor prognosis in certain leukemia subtypes, prompting researchers to investigate its functional properties and molecular mechanisms. Given that ZNF384 serves as a transcriptional regulator, understanding its structure and interactions with other proteins can provide valuable insights into its role in oncogenesis. The expression and characterization of recombinant ZNF384 protein are essential steps toward elucidating its function. Researchers aim to produce this protein to study its biochemical properties, assess its interactions with potential binding partners, and explore its impact on gene expression regulation. Ultimately, the findings from ZNF384 recombinant protein studies may contribute to the development of novel therapeutic strategies targeting its dysregulation in cancer, offering hope for improved treatment options for patients with leukemia and other associated disorders.
